Given the company is probably in the best position it has ever been in terms of product maturity, human trials, ongoing R&D and innovative world class COVID respiratory analysis software then I would conclude the company market capitalisation should equally reflect or exceed a higher valuation it achieved in the past two years, IMHO.
On the 17 June 2020, RAP had a peak share price of $0.19. Thus the current $0.115 takeover offer is still 40% below this previous higher share price.
Therefore, I can see higher highs in share price developing in line with further product development maturity and timely global product release.
Ann: Quarterly Activities Report and Appendix 4C, page-76
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
